Leisure Capital Management Sells 4,868 Shares of Sanofi (NASDAQ:SNY)

Leisure Capital Management lessened its position in Sanofi (NASDAQ:SNY) by 21.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,863 shares of the company’s stock after selling 4,868 shares during the period. Leisure Capital Management’s holdings in Sanofi were worth $888,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Atria Wealth Solutions Inc. grew its position in shares of Sanofi by 7.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 16,370 shares of the company’s stock valued at $814,000 after acquiring an additional 1,205 shares during the period. Wynn Capital LLC bought a new position in shares of Sanofi in the 4th quarter valued at about $251,000. Bfsg LLC bought a new stake in shares of Sanofi during the 4th quarter worth about $71,000. Yousif Capital Management LLC boosted its holdings in shares of Sanofi by 7.1% during the 4th quarter. Yousif Capital Management LLC now owns 44,481 shares of the company’s stock worth $2,212,000 after buying an additional 2,930 shares during the period. Finally, Millington Financial Advisors LLC boosted its holdings in shares of Sanofi by 9.8% during the 4th quarter. Millington Financial Advisors LLC now owns 19,864 shares of the company’s stock worth $988,000 after buying an additional 1,773 shares during the period. Institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Stock Performance

Sanofi stock traded down $0.23 during midday trading on Friday, hitting $49.13. The company’s stock had a trading volume of 4,148,180 shares, compared to its average volume of 2,214,580. The company has a 50-day moving average price of $47.71 and a two-hundred day moving average price of $48.41. The company has a market cap of $124.28 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 1.49 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a 1-year low of $42.63 and a 1-year high of $56.26.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. As a group, sell-side analysts predict that Sanofi will post 4.09 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is presently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.